Since then, IFN-Is, almost exclusively IFN-α, have received additional approvals to treat several neoplastic diseases, including follicular non-Hodgkin lymphoma and resectable stage II and III melanoma, mainly in an adjuvant setting [83]. The gene discussed is IFNA1; the disease is neoplasm.